Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antimicrobial Effectiveness

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Healthcare Associated Infections II: Preventive Measures

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multidrug-resistant Enterobacterales in United States hospitals: Frequency and susceptibility to newer β-lactamase inhibitor combinations (2020-2024).

International journal of antimicrobial agents·2026

Same author

Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025).

Antibiotics (Basel, Switzerland)·2026

Same author

In Vitro Antimicrobial Activity of Ceftobiprole and Comparator Agents Against <i>Streptococcus pneumoniae</i> Responsible for Lower Respiratory Tract Infections in the United States (2016-2020), Including Resistant Subsets and Select Serotypes.

Antibiotics (Basel, Switzerland)·2026

Same author

Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline.

Journal of clinical microbiology·2026

Same author

In vitro activity of ceftobiprole against Gram-positive clinical bacterial isolates causing skin and skin structure infections in the United States.

Diagnostic microbiology and infectious disease·2026

Same author

Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested Against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019-2023).

Antibiotics (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Amplicon Sequencing using the Long-Read Sequencing Technologies

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

Linezolid surveillance program results for 2008 (LEADER Program for 2008).

David J Farrell¹, Rodrigo E Mendes, James E Ross

¹JMI Laboratories, North Liberty, IA 52317, USA. david-farrell@jmilabs.com

Diagnostic Microbiology and Infectious Disease

|November 17, 2009

Summary

The LEADER Program found linezolid remains highly effective against common bacteria in US hospitals. Surveillance in 2008 showed sustained potency, with only 0.36% of strains exhibiting resistance, indicating continued low rates of linezolid nonsusceptibility.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Amplicon Sequencing using the Long-Read Sequencing Technologies

Amplicon Sequencing using the Long-Read Sequencing Technologies

Published on: August 29, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

Antimicrobial resistance surveillance
Clinical microbiology
Infectious disease epidemiology

Background:

The Linezolid Emerging Resistance (LEADER) Program monitors linezolid resistance in US medical centers.
This report details findings from the 5th year of surveillance in 2008.

Purpose of the Study:

To assess the potency and spectrum of linezolid against key bacterial pathogens.
To monitor trends in linezolid nonsusceptibility and identify emerging resistance mechanisms.

Main Methods:

Data collected from 57 US medical centers in 2008.
Testing of 6113 bacterial isolates including Staphylococcus aureus, coagulase-negative staphylococci (CoNS), enterococci, and streptococci.
Reference broth microdilution and D-test methods were employed.

Main Results:

Linezolid demonstrated high potency with MIC(90) values ranging from 1-2 µg/mL.
Overall linezolid nonsusceptibility was low at 0.36%, a decrease from previous years.
Identified resistance mechanisms included target mutations and the mobile cfr element, with no evidence of widespread dissemination of cfr in 2008.

Conclusions:

Linezolid maintains excellent activity against a broad range of bacteria in US healthcare settings.
Nonsusceptible strain isolation rates remained stable, with no significant increase in plasmid-mediated resistance.
The LEADER Program effectively tracks oxazolidinone resistance phenotypes and genotypes, highlighting sustained linezolid potency.